Verisign Reports Internet Has 350.4 Million Domain Name Registrations at the End of the Fourth Quarter of 2022
VeriSign, Inc. (NASDAQ: VRSN), a global provider of domain name registry services and internet infrastructure, today announced that the fourth quarter of 2022 closed with 350.4 million domain name registrations across all top-level domains (TLDs), an increase of 0.5 million domain name registrations, or 0.1%, compared to the third quarter of 2022.1,2 Domain name registrations have increased by 8.7 million, or 2.6%, year over year.1,2
The .com and .net TLDs had a combined total of 173.8 million domain name registrations in the domain name base3 at the end of the fourth quarter of 2022, a decrease of 0.4 million domain name registrations, or 0.2%, compared to the third quarter of 2022. The .com and .net TLDs had a combined increase of 0.3 million domain name registrations, or 0.2%, year over year. As of Dec. 31, 2022, the .com domain name base totaled 160.5 million domain name registrations, and the .net domain name base totaled 13.2 million domain name registrations.
New .com and .net domain name registrations totaled 9.7 million at the end of the fourth quarter of 2022, compared to 10.6 million domain name registrations at the end of the fourth quarter of 2021.
Total country-code TLD (ccTLD) domain name registrations were 133.1 million at the end of the fourth quarter of 2022, an increase of 0.7 million domain name registrations, or 0.5%, compared to the third quarter of 2022.1,2 ccTLDs increased by 5.7 million domain name registrations, or 4.5%, year over year. The top 10 ccTLDs, as of Dec. 31, 2022, were .cn, .de, .uk, .nl, .ru, .br, .au, .eu, .fr, and .it.1,2
Verisign publishes The Domain Name Industry Brief to provide internet users throughout the world with statistical and analytical research and data on the domain name industry. The Domain Name Industry Brief for the fourth quarter 2022, as well as previous briefs, can be obtained at verisign.com/dnib.
About Verisign
Verisign, a global provider of domain name registry services and internet infrastructure, enables internet navigation for many of the world’s most recognized domain names. Verisign enables the security, stability, and resiliency of key internet infrastructure and services, including providing root zone maintainer services, operating two of the 13 global internet root servers, and providing registration services and authoritative resolution for the .com and .net top-level domains, which support the majority of global e-commerce. To learn more about what it means to be Powered by Verisign, please visit verisign.com.
VRSN
© 2023 VeriSign, Inc. All rights reserved. VERISIGN, the VERISIGN logo, and other trademarks, service marks, and designs are registered or unregistered trademarks of VeriSign, Inc. and its subsidiaries in the United States and in foreign countries. All other trademarks are property of their respective owners.
1 All figure(s) exclude domain names in the .tk, .cf, .ga, .gq, and .ml ccTLDs. Quarterly and year-over-year trends have been calculated relative to historical figures that have also been adjusted to exclude these five ccTLDs. For further information, please see the Editor’s Note contained in Vol. 19, Issue 1 of The Domain Name Industry Brief.
2The generic TLD, ngTLD, and ccTLD data cited in the brief: (i) includes ccTLD internationalized domain names, (ii) is an estimate as of the time the brief was developed ad (iii) is subject to change as more complete data is received. Some numbers in the brief may reflect standard rounding.
3 The domain name base is the active zone plus the number of domain names that are registered but not configured for use in the respective TLD zone file plus the number of domain names that are in a client or server hold status. The .com and .net domain name registration figures are as reported in Verisign’s most recent SEC filings.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230309005753/en/
Contact information
Investor Relations: David Atchley, datchley@verisign.com, + 1 703-948-3447
Media Relations: Dave McGuire, davmcguire@verisign.com, + 1 703-948-3800
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ireland Unveils Seven New Halloween Experiences30.10.2025 16:00:00 EET | Press release
With seven brand-new Halloween hubs or experiences launching across the island this month, Ireland has truly become the ultimate destination to celebrate Halloween in 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251022209535/en/ Derry Halloween Festival, County Derry~Londonderry Ireland’s Halloween Season Rooted in the ancient Celtic festival of Samhain, Halloween originated in Ireland more than 2,000 years ago and, this year, the island of Ireland is expanding its celebration like never before. With over 340 events planned across the island to celebrate this year, Halloween in Ireland is fast becoming a bucket-list travel experience. Seven new Halloween hubs join existing flagship events across the island of Ireland including the Púca Festival in County Meath and Derry Halloween in Derry-Londonderry which together welcomed over 169,000 visitors last year. The seven new hubs are inviting visitors to come and explore
Staloral ® Birch Phase III Study Successfully Meets Primary Endpoint, Demonstrating Efficacy in Children and Adolescents30.10.2025 15:56:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, announced today that its Phase IIIb clinical study (YOBI, YOung patients and BIrch allergy), designed to confirm the safety and efficacy of Staloral® Birch in children and adolescents with birch pollen-induced allergic rhino-conjunctivitis (ARC), with or without asthma, has successfully achieved its primary endpoint. The trial enrolled 553 children aged 5 -17 years with moderate to severe birch pollen-induced ARC, with or without asthma, across 64 sites in 12 European countries and assessed the efficacy and safety of Staloral® birch 300IR daily maintenance dose administered pre-and co-seasonally over two consecutive birch pollen seasons. The YOBI study successfully met its primary endpoint, demonstrating the efficacy of Staloral® Birch in a paediatric population (5-17) with a 41% improvement in the ARC total combined score during the second pollen season compared to placebo. These results were highly statistically significant
Andersen Consulting Enhances Its Platform Through Collaboration With threon30.10.2025 15:30:00 EET | Press release
Andersen Consulting deepens its business transformation and digital transformation capabilities through a Collaboration Agreement with threon, a Belgium-based consultancy known for delivering pragmatic, end-to-end strategy execution support. For more than 20 years, threon has been a trusted advisor for organizations looking to turn big ideas into delivering true business impact. The firm brings together their expertise in strategic portfolio management, digital transformation, and executive training to help leaders move from vision to execution. Threon’s unique approach blends project delivery, workforce development, and smart software solutions, empowering teams to deliver faster, scale with confidence, and achieve lasting results. CEO of threon Tom Dedecker said, “We bring focus and peace to organizations, enabling faster decision-making and sustainable transformation rooted in their unique identity.” Eric Noerdinger, managing director of threon added, “Our goal is to embed change su
Bending Spoons Raises $710M for Continued Investment and Growth30.10.2025 15:00:00 EET | Press release
Bending Spoons, one of Europe’s leading technology companies, today announced it has raised $710 million in equity at a pre-money valuation of $11 billion. The round was led by accounts advised by T. Rowe Price Investment Management, Inc., with participation from Baillie Gifford, Cox Enterprises, Durable Capital Partners, Fidelity Management & Research Company, Foxhaven Asset Management, and Radcliff, among others. Goldman Sachs International acted as sole placement agent and Clifford Chance served as legal advisor to the transaction. Notarial advisory services were provided by ZNR Notai. “This moment is a validation of a decade’s worth of work and it serves as an important recognition of what we’ve accomplished at Bending Spoons so far. We remain early in our journey and have ambitious plans for continued investment and growth,” shares Luca Ferrari, co-founder and CEO of Bending Spoons. “We’re proud to bring on some of the world’s finest investors who believe in our approach to value
Debiopharm Forges AI-powered Alliance With NetTargets to Pioneer Dual-payload ADCs Against Drug-resistant Cancers30.10.2025 15:00:00 EET | Press release
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company dedicated to developing innovative therapies that respond to high unmet medical needs, today announced a strategic research collaboration with NetTargets (www.net-targets.com), a South Korean biotech company specializing in AI-enhanced systems biology for drug discovery, to rationally design and advance the discovery of novel, synergistic drug combinations for Debiopharm’s next-generation Antibody-Drug Conjugates (ADCs). This alliance unites NetTargets' sophisticated artificial intelligence (AI) platform with Debiopharm's proprietary MLINKtechnology to create a new paradigm in cancer treatment, aiming to deliver a decisive, dual-action blow against treatment-resistant tumors. This collaboration achieves this multi-pronged strategy by uniting two cutting-edge technologies: NetTargets' AI-Powered Discovery Engine and Debiopharm's MLINK Duo Technology. NetTargets' proprietary AI platform integrates
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom